Automated fully closed-loop insulin delivery improves type 2 diabetes outcomes, research finds

Fully closed-loop insulin delivery is better at improving glucose control without increasing hypoglycaemia risk compared to standard insulin therapy, a new study shows.

Researchers have found that fully automated closed-loop insulin delivery systems are a safe and efficaciousmethod to improve outcomes in adults with type 2 diabetes.

During the randomised study, 26 adults with type 2 diabetes underwent two eight-week periods to compare the CamAPS HX fully closed-loop app with traditional insulin therapy and a masked glucose sensor.

The results state: “Proportion of time in target glucose range was 66.3 per cent ± 14.9 per cent with closed-loop therapy versus 32.3 per cent ± 24.7 per cent with control therapy.

“Time > 10 mmol/L was 33.2 per cent ± 14.8 per cent with closed-loop therapy versus 67 per cent ± 25.2 per cent with control therapy. Mean glucose was lower during the closed-loop therapy period than during the control therapy period.”

The findings add: “HbA1c was lower following closed-loop therapy than following control therapy; mean difference, -15 mmol/mol; 95 per cent, -11 to -20 mmol/L.

“Time < 3.9 mmol/L was similar between treatments during the closed-loop therapy period versus a median of 0.08 per cent during the control therapy period. No severe hypoglycaemia events occurred in either period. One treatment-related serious adverse event occurred during the closed-loop therapy period.”

CamAPS HX is a fully automated closed-loop insulin delivery system designed by CamDiab – a company paving the way for the future of diabetes care with the world’s first artificial pancreas.

CamDiab also has a commercially available hybrid closed-loop system for use in people with type 1 diabetes (from the age of one years) called CamAPS FX.

To read the research, click here.